AU2002213001A1 - Methods and compositions for modulating T cell activation and uses thereof - Google Patents

Methods and compositions for modulating T cell activation and uses thereof

Info

Publication number
AU2002213001A1
AU2002213001A1 AU2002213001A AU1300102A AU2002213001A1 AU 2002213001 A1 AU2002213001 A1 AU 2002213001A1 AU 2002213001 A AU2002213001 A AU 2002213001A AU 1300102 A AU1300102 A AU 1300102A AU 2002213001 A1 AU2002213001 A1 AU 2002213001A1
Authority
AU
Australia
Prior art keywords
ncam
cell
fragment
functional derivative
cell activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213001A
Other languages
English (en)
Inventor
Larissa Balaian
Anthony Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2002213001A1 publication Critical patent/AU2002213001A1/en
Assigned to THE SCRIPPS RESEARCH INSTITUTE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment THE SCRIPPS RESEARCH INSTITUTE Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2002213001A 2000-10-02 2001-10-02 Methods and compositions for modulating T cell activation and uses thereof Abandoned AU2002213001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23755500P 2000-10-02 2000-10-02
US60237555 2000-10-02
PCT/US2001/030864 WO2002028440A1 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Publications (1)

Publication Number Publication Date
AU2002213001A1 true AU2002213001A1 (en) 2002-04-15

Family

ID=22894231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213001A Abandoned AU2002213001A1 (en) 2000-10-02 2001-10-02 Methods and compositions for modulating T cell activation and uses thereof

Country Status (5)

Country Link
EP (1) EP1328298A4 (fr)
JP (1) JP2004531457A (fr)
AU (1) AU2002213001A1 (fr)
CA (1) CA2423436A1 (fr)
WO (1) WO2002028440A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018089628A1 (fr) 2016-11-09 2018-05-17 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP1328298A4 (fr) 2005-05-04
WO2002028440A1 (fr) 2002-04-11
EP1328298A1 (fr) 2003-07-23
WO2002028440B1 (fr) 2002-05-30
JP2004531457A (ja) 2004-10-14
CA2423436A1 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
Harris et al. The role of B7 costimulation in T‐cell immunity
AU2009288730B2 (en) Compositions of PD-1 antagonists and methods of use
Linsley et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Freeman et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
EP1234031B2 (fr) Nouvelle molécule immunorégulatrice b7-h1,
US6451305B1 (en) Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand
Wallace et al. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment.
JP2002356443A (ja) 炎症性腸疾患治療剤
ZA200208897B (en) Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking LFA-1 mediated adhesion.
Chitnis et al. Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis
Scheipers et al. Role of the CTLA-4 receptor in T cell activation and immunity: physiologic function of the CTLA-4 receptor
Rietz et al. New B7 family members with positive and negative costimulatory function
Balaian et al. The human neural cell adhesion molecule L1 functions as a costimulatory molecule in T cell activation
AU2002213001A1 (en) Methods and compositions for modulating T cell activation and uses thereof
US20030040477A1 (en) Methods and compositions for modulating t cell activation and uses thereof
US20070009517A1 (en) Method of inducing immune tolerance
Walker ME (Linda) Joosse Iris Nederlof Lucy SK Walker Janneke N. Samsom
Buhlmann et al. 1. WHAT IS COSTIMULATION?
Linsley Immunosuppression and the CD28 receptor
Alenzi et al. Role of CTLA-4 in xenotranplantation
Yang et al. The role of B7-2 (CD86) in tumour immunity
Liu et al. THE MOLECULAR BASIS OF T CELL COSTIMULATION
Goldberg et al. Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production By Gordon J. Freeman,* Frank Borrielloj Richard J. Hodes's Hans Reiser, ll John G. Gribben'Judy W. Ng,* Jinny Kim, $
Alegre et al. CTLA-4: Its Role in the Immune Response
Pastorino Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted